[Passive immunotherapy with polyvalent immunoglobulins in women with habitual abortions].
Intravenous immunoglobulins (IVIG) were used in an alternative approach to immunotherapy with allogeneic leukocytes to prevent recurrent spontaneous abortions (RSA). Twenty five women with a history of greater than or equal to 3 unexplained RSA were treated with IVIG during their next pregnancy. An initial dose of 30 g (0.5-0.6 g/kg body weight) was administered at gestational week 5-6. Treatment was continued every 3 weeks with 20 g (0.3-0.4 g/kg) and terminated by week 25. In primary RSA the success rate was 82-85%, which is in the same range as for leukocyte therapy. In contrast, IVIG was successful in only 40% of secondary aborters. We conclude that IVIG can be an effective treatment for prevention of primary RSA. Compared to leukocyte therapy the risks of transmission of infections and of HLA immunization can be avoided.
Mueller-Eckhardt
G
G
Institut für Klinische Immunologie und Transfusionsmedizin, Justus-Liebig-Universität Giessen.
Heine
O
O
Turba
H
H
Berghöfer
A
A
Neppert
J
J
Künzel
W
W
Mueller-Eckhardt
C
C
D000026:Abortion, Habitual / Q000276:immunology / Q000628:therapy*; D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007116:Immunization, Passive / Q000379:methods*; D007231:Infant, Newborn; D011247:Pregnancy
Passive Immuntherapie mit polyvalenten Immunglobulinen bei Frauen mit habituellen Aborten.